Zimmer Biomet (ZBH) Expected to Announce Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is expected to be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Zimmer Biomet to post earnings of $1.87 per share and revenue of $2.0089 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

ZBH stock opened at $101.18 on Wednesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market capitalization of $20.04 billion, a P/E ratio of 24.62, a P/E/G ratio of 2.37 and a beta of 0.67. The business’s 50-day moving average is $101.81 and its two-hundred day moving average is $97.63. Zimmer Biomet has a 1 year low of $89.22 and a 1 year high of $114.72.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore ISI reduced their price target on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a research report on Friday, October 10th. UBS Group raised their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $101.00 target price on shares of Zimmer Biomet in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $111.94.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors have recently added to or reduced their stakes in ZBH. Orion Porfolio Solutions LLC purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $426,000. State of Wyoming purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $124,000. Headlands Technologies LLC purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $37,000. Corient Private Wealth LLC boosted its holdings in Zimmer Biomet by 78.8% in the 2nd quarter. Corient Private Wealth LLC now owns 105,077 shares of the medical equipment provider’s stock worth $9,585,000 after acquiring an additional 46,317 shares during the period. Finally, Chapman Financial Group LLC purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $218,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.